Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer

2008

Changes in PDGFR and Survival in Prostate Cancer After Docetaxel Therapy

Sample size: 116 publication 10 minutes Evidence: moderate

Author Information

Author(s): Mathew P, Thall P F, Wen S, Bucana C, Jones D, Horne E, Oh W K, Morris M J, Lee Y-C, Logothetis C J, Lin S-H, Fidler I J

Primary Institution: MD Anderson Cancer Center

Hypothesis

Does the dynamic change in phosphorylated platelet-derived growth factor receptor (PDGFR) in peripheral blood leukocytes predict progression-free and overall survival in prostate cancer patients undergoing docetaxel therapy?

Conclusion

The study suggests that changes in PDGFR phosphorylation can predict the efficacy of docetaxel therapy in prostate cancer patients.

Supporting Evidence

Patients with a decrease in PDGFR phosphorylation had a median progression-free survival of 3.3 months compared to 6.8 months for those without.
In the docetaxel plus placebo group, a decrease in PDGFR phosphorylation was associated with inferior overall survival.
The study involved 116 men with prostate cancer, providing a substantial sample size for analysis.

Takeaway

This study found that measuring a specific protein in the blood can help doctors understand how well a cancer treatment is working.

Methodology

A randomized placebo-controlled trial was conducted to assess the effects of docetaxel with or without imatinib on prostate cancer patients, measuring PDGFR phosphorylation and plasma PDGF levels.